
Innovative Molecules Enters Phase 2a Trials for Adibelivir
Munich-based Innovative Molecules has dosed the first patient in its Phase 2a trial of adibelivir, a novel oral treatment for recurrent genital herpes. This milestone shifts the company’s lead program into proof-of-concept development, marking a pivotal transition toward late-stage clinical evaluation for the biotechnology firm.

























